AI-Empowered Mechanomedicine for Cancer-Related Lymphedema
Research · 01.01.2026 · 9
DOI: 10.34133/research.1383 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Research, online erschienen am 04.08.2026. Verfasst von Zhe Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rehabilitation Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, P.R. China. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Key Project of National Natural Science Foundation of China, National Natural Science Foundation Key International Cooperative Research Project, Key Research and Development Projects of Shaanxi Province.
Abstract (Originalsprache)
Cancer-related lymphedema is a chronic progressive side effect of cancer treatments followed by lymph node dissection or radiotherapy. Clinicians often identify lymphedema through limb swelling, while the disease begins earlier than that. Lymphatic injury is the original cause, where elevated interstitial fluid pressure and distorted tissue mechanics will lead to immune activation and fibrofatty remodeling. Recently, mechanobiology studies have deepened our understanding by linking lymph stasis to T helper 2/transforming growth factor β signaling, fibroblast mechanotransduction, and YAP/TAZ activity that together lock tissues into a stiff, poorly draining state. Simultaneously, emerging artificial intelligence (AI) in the field are being explored, from proof-of-concept image classification to much more diagnostic models that integrate elastography, indocyanine green lymphography, radiomics, clinical variables, and wearable signals to detect preclinical mechanical signatures and predict risk. These advances are driving the development of promising mechanomedical approaches, such as adaptive compression systems, AI-assisted plans for lymphatic reconstruction, anti-fibrotic strategies, and lymphangiogenic regeneration, although most remain at preclinical or early clinical feasibility stages of translation. We discuss the strength of current evidence, challenges for clinical translation, and standards for reporting. We propose that cancer-related lymphedema can be understood as a measurable and targetable mechano-immune-fibrotic disease, for which AI may eventually support earlier diagnosis, risk prediction, and personalized mechanotherapy.
Autor:innen und Institutionen
- Department of Rehabilitation Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, P.R. China.
- Bioinspired Engineering and Biomechanics Center (BEBC), Xi'an Jiaotong University, Xi'an 710049, P.R. China.
- The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an 710049, P.R. China.
- Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou 570311, P.R. China.
ORCID-Profile: Feng Xu
Förderung
- Key Project of National Natural Science Foundation of China
- National Natural Science Foundation Key International Cooperative Research Project
- Key Research and Development Projects of Shaanxi Province
Zitieren
APA
Liu, Z., Gonzalez, O., You, M., Xu, F., & Wen, T. (2026). AI-Empowered Mechanomedicine for Cancer-Related Lymphedema. Research, 9. https://doi.org/10.34133/research.1383
Vancouver
Liu Z, Gonzalez O, You M, Xu F, Wen T. AI-Empowered Mechanomedicine for Cancer-Related Lymphedema. Research. 2026;9. doi:10.34133/research.1383
BibTeX
@article{Liu2026,
author = {Liu, Zhe and Gonzalez, Oscar and You, Minli and Xu, Feng and Wen, Ting},
title = {AI-Empowered Mechanomedicine for Cancer-Related Lymphedema},
journal = {Research},
year = {2026},
volume = {9},
doi = {10.34133/research.1383}
}
EUVIMED